F10 and autoimmune hemolytic anemia: Bypassing agents are widely used for the hemostatic treatment of AHA and comprised of recombinant activated factor VII (rFVIIa), activated prothrombin complex concentrate (aPCC) [1] and plasma-derived factor VIIa and factor X (FVIIa/FX) launched only in Japan [13].